Core E - Virology, Next-Generation Sequencing and Imaging Core E is the main resource provided by the CFAR to support virological investigations of HIV/SIV and studies of its co-pathogens, such as Mycobacterium tuberculosis (Mtb) and Hepatitis C Virus (HCV). The Core has been configured to provide a wide range of services in support of modern virology research that now includes novel services for the rapid creation of recombinant viruses, production of recombinant virus and lentivirus vector stocks, support of shRNA library screens, high throughput, next-generation DNA sequencing (NGS). and access to high resolution fluorescence and electron microscopy technologies.
The specific aims of the Virology, Next Generation Sequencing and Imaging core are: ? Virology: To provide access to panels of primary and recombinant HIV and SIV strains and recombinant yeast technology to create novel viral variants. The core maintains a repository of over 500 well- characterized primary HIV isolates as well as common and novel recombinant laboratory proviral constructs. Ongoing services include HIV, SIV, and lentiviral vector production and assay, provided on a per protocol basis. The core will also provide support for new technologies for shRNA library screens, which are in demand by numerous CFAR supported laboratories. ? Next Generation Sequencing (NGS): Provide access to the latest technologies in ultra-deep sequencing, including Ion Torrent, Roche 454, and Illumina platforms, in a CLIA/CAP (Clinical Laboratory Improvement Amendments/College of American Pathologists) accredited laboratory. In addition to offering the only deep sequencing-based HIV-1 Genotyping and Coreceptor Tropism Assay currently commercially available worldwide (DEEPGEN?HIV), the core has ample expertise and offers training in library preparation and assessment, sequencing, and bioinformatic analysis for both basic and clinical research projects. ? Imaging: Provide access and support for state-of-the-art fluorescence and electron microscopy across multiple platforms. The core houses a Deltavision fluorescence microscopy system within a biocontainment laboratory for live-cell experiments on HIV infected samples. The core supports other imaging platforms through strategic investments in Case imaging facilities to facilitate cross-campus collaborative interactions. In summary, Core E is provides invaluable support for HIV-1 projects involving molecular and cellular virology. The Core is continuously pushing forward new technologies that are not accessible to individual laboratories due to their high cost or degree of specialization. The Core will continue to extensive training and advice to its users and advance new technologies that fulfill unmet needs for the current and future HIV research priorities of the Case/UH CFAR.

Public Health Relevance

Core E The HIV/AIDS pandemic is the single largest threat to global public health. This core provides essential tools in support of basic and clinical research in the Case/UH CFAR, including provision of HIV isolates and state- of-the-art microscopy and DNA sequencing technologies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036219-24
Application #
9468330
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
24
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Webel, Allison R; Perazzo, Joseph; Longenecker, Christopher T et al. (2018) The Influence of Exercise on Cardiovascular Health in Sedentary Adults With Human Immunodeficiency Virus. J Cardiovasc Nurs 33:239-247
Yan, Junpeng; Shun, Ming-Chieh; Hao, Caili et al. (2018) HIV-1 Vpr Reprograms CLR4DCAF1 E3 Ubiquitin Ligase to Antagonize Exonuclease 1-Mediated Restriction of HIV-1 Infection. MBio 9:
Silver, Nicholas; Paynter, Mary; McAllister, Georgina et al. (2018) Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. AIDS Res Ther 15:18
Jiang, Wei; Luo, Zhenwu; Martin, Lisa et al. (2018) Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy. Curr HIV Res 16:143-150
Martinez, Leonardo; Handel, Andreas; Shen, Ye et al. (2018) A Prospective Validation of a Clinical Algorithm to Detect Tuberculosis in Child Contacts. Am J Respir Crit Care Med 197:1214-1216
Fitzgerald, Wendy; Freeman, Michael L; Lederman, Michael M et al. (2018) A System of Cytokines Encapsulated in ExtraCellular Vesicles. Sci Rep 8:8973
Dazard, Jean-Eudes; Ishwaran, Hemant; Mehlotra, Rajeev et al. (2018) Ensemble survival tree models to reveal pairwise interactions of variables with time-to-events outcomes in low-dimensional setting. Stat Appl Genet Mol Biol 17:
Mukherjee, Pranab K; Chandra, Jyotsna; Retuerto, Mauricio et al. (2018) Dysbiosis in the oral bacterial and fungal microbiome of HIV-infected subjects is associated with clinical and immunologic variables of HIV infection. PLoS One 13:e0200285
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Tomalka, Amanda G; Resto-Garay, Ivelisse; Campbell, Kerry S et al. (2018) In vitro Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells. Front Immunol 9:2552

Showing the most recent 10 out of 539 publications